Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Revance Therapeutics (RVNC) Misses Q2 EPS by 12c
August 9, 2022 5:00 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.12 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $28.15 million.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More